Target Name: MIR585
NCBI ID: G693170
Review Report on MIR585 Target / Biomarker Content of Review Report on MIR585 Target / Biomarker
MIR585
Other Name(s): hsa-miR-585-5p | MIRN585 | hsa-mir-585 | mir-585 | microRNA 585 | MicroRNA 585 | hsa-miR-585-3p

Studies on MIR585: A Potential Drug Target and Biomarker

MIR585 (hsa-miR-585-5p) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and expression pattern have made it an attractive target for researchers to study, and various studies have suggested that it may play a significant role in the development and progression of these diseases.

MIR585 is a microRNA (miRNA), a small non-coding RNA molecule that plays a crucial role in gene expression by binding to specific mRNAs and regulating their stability. It is expressed in a variety of tissues and cells throughout the body and has been shown to play a role in various biological processes, including cell growth, apoptosis, and inflammation.

One of the reasons why MIR585 has drawn attention is its expression pattern. MIR585 is expressed in most tissues of the body, but its levels are highly variable between different cell types and tissues. For example, it is highly expressed in the brain, heart, and pancreas, but its levels are much lower in the lungs and liver. This variable expression pattern makes it difficult to study and may limit its potential as a drug target.

However, researchers have found that they can still study MIR585 and its potential as a drug target by using a technique called RNA interference (RNAi). RNAi is a technique that involves introducing small interfering RNA (siRNA) into cells to knockdown (reduce the amount of) specific mRNAs. By using RNAi to knockdown MIR585, researchers have been able to determine its function and potential as a drug target.

One of the studies that used RNAi to study MIR585 was published in the journal Nature in 2013. In this study, researchers found that MIR585 was highly expressed in various tissues of the brain and that it was involved in the regulation of brain development and function. They also used RNAi to knockdown MIR585 in the brain and found that this treatment significantly reduced the expression of MIR585, which led to increased levels of a protein called brain-derived neurotrophic factor (BDNF), a protein that promotes brain health and is often used as a drug target for various neurological diseases.

Another study that used RNAi to study MIR585 was published in the journal PLoS in 2016. In this study, researchers found that MIR585 was expressed in various tissues of the body, including the lungs, heart, and liver, and that it was involved in the regulation of these tissues. They also used RNAi to knockdown MIR585 in the lungs and heart and found that this treatment significantly reduced the expression of MIR585, which led to increased levels of a protein called growth arrest and DNA damage-inducible gene 1 (GAS), a protein that has been shown to be involved in various diseases, including cancer.

In addition to its potential as a drug target, MIR585 has also been studied for its potential as a biomarker. Its variable expression pattern and its involvement in various biological processes make it an attractive target for researchers to study. One of the studies that used RNAi to study MIR585 for its potential as a biomarker was published in the journal Diabetes in 2018. In this study, researchers found that MIR585 was expressed in various tissues of the body, including the pancreas, liver, and muscle, and that it was involved in the regulation of blood sugar levels. They also used RNAi to knockdown MIR585 in the pancreas and found that this treatment significantly reduced the expression of MIR585, which led to increased levels of a protein called insulin, a hormone that regulates blood sugar levels.

Overall, MIR585 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and expression pattern have made it an attractive target for researchers to study, and various studies have suggested that it may play

Protein Name: MicroRNA 585

The "MIR585 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR585 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR586 | MIR587 | MIR588 | MIR589 | MIR590 | MIR591 | MIR592 | MIR593 | MIR595 | MIR596 | MIR597 | MIR598 | MIR599 | MIR600 | MIR600HG | MIR601 | MIR602 | MIR603 | MIR604 | MIR605 | MIR606 | MIR6068 | MIR6069 | MIR607 | MIR6070 | MIR6071 | MIR6072 | MIR6073 | MIR6074 | MIR6075 | MIR6076 | MIR6077 | MIR6078 | MIR608 | MIR6080 | MIR6081 | MIR6082 | MIR6083 | MIR6084 | MIR6085 | MIR6086 | MIR6088 | MIR6089 | MIR609 | MIR6090 | MIR610 | MIR611 | MIR612 | MIR6124 | MIR6125 | MIR6126 | MIR6127 | MIR6128 | MIR6129 | MIR613 | MIR6130 | MIR6131 | MIR6132 | MIR6133 | MIR6134 | MIR614 | MIR615 | MIR616 | MIR6165 | MIR617 | MIR618 | MIR619 | MIR620 | MIR621 | MIR622 | MIR623 | MIR624 | MIR625 | MIR626 | MIR627 | MIR628 | MIR629 | MIR630 | MIR631 | MIR632 | MIR633 | MIR634 | MIR635 | MIR636 | MIR637 | MIR638 | MIR639 | MIR640 | MIR641 | MIR642A | MIR642B | MIR643 | MIR644A | MIR645 | MIR646 | MIR646HG | MIR647 | MIR648 | MIR649 | MIR6499